We are live on ! Find out more
CELG.RT icon

Bristol-Myers Squibb Rights

28 hedge funds and large institutions have $248K invested in Bristol-Myers Squibb Rights in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

4% more funds holding

Funds holding: 27 → 28 (+1)

0% less ownership

Funds ownership: 0.02% → 0.02% (-0%)

22% less capital inflows, than outflows

Capital inflows: $65.4K | Capital outflows: $84.1K

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
28
Holders Change
+1
Holders Change %
+3.7%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
3
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CELG.RT Hedge Fund Activity: Q2 2020 in Review

28 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q2 2020, worth a combined $248K — down 15% from $291K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CELG.RT positions and 6 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.

The largest buyer was 55I LLC, opening a new position worth an estimated $38.9K. The largest seller was Transcend Capital Advisors, exiting entirely with an estimated $56K sold.

  • 28 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q2 2020, up from 27 in Q1 2020.
  • Funds reported $248K of Bristol-Myers Squibb Rights stock for Q2 2020, down 15% quarter-over-quarter.
  • 7 funds opened new Bristol-Myers Squibb Rights positions in Q2 2020 and 6 closed out, a net change of +1 holder.
  • The largest Bristol-Myers Squibb Rights buyer in Q2 2020 was 55I LLC, an estimated $38.9K added.
  • The largest Bristol-Myers Squibb Rights seller in Q2 2020 was Transcend Capital Advisors, an estimated $56K sold.

Based on aggregated 13F filings for Q2 2020.